Showing results (161-170 of 181) with videos related to
Sort By:
Pageof 19
International Journal of Clinical Oncology|August 8, 2023
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years oldMizuki Kobayashi, Kazuyuki Numakura, Shingo Hatakeyama, et al.International Journal of Clinical Oncology|June 30, 2021
Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy eraSei Naito, Tomoyuki Kato, Kazuyuki Numakura, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|July 4, 2025
Impact of Impaired Renal Function on the Efficacy and Safety of Second-Line Tyrosine Kinase Inhibitor Therapy After First-Line Immuno-Oncology Combination Therapy in Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective StudyNaoki Fujita, Yuto Matsushita, Takahiro Kojima, et al.International Journal of Clinical Oncology|June 11, 2020
A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world dataNobuyuki Hinata, Junji Yonese, Satoru Masui, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|December 13, 2021
Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomyNobutaka Nishimura, Makito Miyake, Kota Iida, et al.Cancer Science|July 18, 2022
Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumabShuhei Takahashi, Shintaro Narita, Nobuhiro Fujiyama, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|January 19, 2024
Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapyYuto Matsushita, Takahiro Kojima, Takahiro Osawa, et al.World Journal of Urology|March 21, 2024
Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysisNobutaka Nishimura, Makito Miyake, Kota Iida, et al.Scientific Reports|November 23, 2023
Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective studyTomokazu Sazuka, Yuto Matsushita, Hiroaki Sato, et al.Cancer Science|November 17, 2024
Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinomaKanami Mori, Kazuyuki Numakura, Yuto Matsushita, et al.Pageof 19